Psychiatry Research
May 1, 2024
Bruno Romeo, Ewen Kervadec, Baptiste Fauvel et al.
48 citations
Psychotherapies assisted by psychedelic substances have shown promising results in the treatment of psychiatric disorders. The aim of this systematic review and meta-analysis was to evaluate safety data in human subjects. We carried out a search on MEDLINE, Embase and PsycINFO databases between 2000 and 2022. Standardized mean differences between different dose ranges and between acute and...
Psychiatric News
April 23, 2024
Terri D’arrigo
announced in April that the Food and Drug Administration (FDA) approved the antipsychotic Fanapt (iloperidone) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. Iloperidone has been approved for the acute treatment of schizophrenia since 2009. The approval was based on a phase 3 clinical trial of 414 adults with a history of bipolar I disorder....
Journal For International Medical Graduates
April 18, 2024
Sarosh Nawaz, Abdulaziz Mohammed Althwanay, B Esraa M. Aledani Mb Ch et al.
The impact of psychedelic treatment on patients suffering from psychiatric diseases like depression, anxiety, post-traumatic psychiatric disorder (PTSD), and existential distress related to cancer has become very intriguing to psychiatrists in the modern era. Serotonergic psychedelics include Lysergic acid diethylamide (LSD), psilocybin, mescaline, ayahuasca, and methylene-deoxy methamphetamine...
Translational Psychiatry
April 15, 2024
Nathan Allen, Aron Jeremiah, Robin J Murphy et al.
15 citations
Microdosing psychedelic drugs at a level below the threshold to induce hallucinations is an increasingly common lifestyle practice. However, the effects of microdosing on sleep have not been previously reported. Here, we report results from a Phase 1 randomized controlled trial in which 80 healthy adult male volunteers received a 6-week course of either LSD (10 µg) or placebo with doses...
Drug Addiction Mechanisms in the Brain
April 8, 2024
Jayalakshmi Krishnan
LSD is a potent hallucinogen. It was first synthesised in 1938. It is marketed under numerous names. Ergot, a fungus that develops on rye and grains, is used to make LSD. The effect of LSD is mind-altering, pleasurable, and stimulating. Sometimes, exposure to this drug causes so-called unpleasant experiences, such as “bad trips”. It is classified as a Class 1 drug (highly abused) by the Drug...
European Psychiatry
April 1, 2024
P. Castro, J. Maia
IntroductionPsychedelics are substances consumed for recreational use, the majority of these psychoactive substances are illegal and hard to obtain. Therefore, there is a demand for psychedelics legal and easier to access, these types of drugs are called ‘legal highs’. LSA (lysergic acid amide) is one of these new psychoactive substances, this drug is searched because it is known to have an...
Neuropsychopharmacology
April 1, 2024
Hanna Molla, Royce Lee, Ilaria Tare et al.
37 citations
Recent studies and anecdotal reports suggest that psychedelics can improve mood states, even at low doses. However, few placebo-controlled studies have examined the acute effects of low doses of LSD in individuals with psychiatric symptoms. In the current study, we examined the acute and sub-acute effect of a low dose of LSD (26 µg) on subjective effects and mood in volunteers with mild...
Clinical Toxicology
April 1, 2024
Rachael Wilkes, Darren M Roberts, Paul Liknaitzky et al.
8 citations
The global use of certain classical psychedelics has increased in recent years, but little is known about their spectrum of toxicity within Australia. We aim to describe calls to New South Wales Poisons Information Centre relating to exposures to classical psychedelics including lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine, ayahuasca, mescaline and ibogaine. This is a...
ACS Pharmacology & Translational Science
March 8, 2024
Grant C. Glatfelter, Eline Pottie, John S. Partilla et al.
28 citations
Lisuride is a non-psychedelic serotonin (5-HT) 2A receptor (5-HT2A) agonist and analogue of the psychedelic lysergic acid diethylamide (LSD). Lisuride also acts as an agonist at the serotonin 1A receptor (5-HT1A), a property known to counter psychedelic effects. Here, we tested whether lisuride lacks psychedelic activity due to a dual mechanism: (1) partial agonism at 5-HT2A and (2) potent...
Psychedelic Medicine
March 1, 2024
Justin C Strickland, Albert Garcia‐romeu, Matthew W Johnson
20 citations
The Mystical Experience Questionnaire (MEQ-30) and Challenging Effects Questionnaire (CEQ) are two of the most widely used, validated instruments to probe subjective effects of psychedelic drugs. However, these assessments are lengthy and can be a burden to study participants or patients if administered during acute psychedelic effects, after resolution of psychedelic effects when participants...
Scientific Reports
February 22, 2024
Ethan V Hagen, Melike Schalomon, Yanbo Zhang et al.
11 citations
The therapeutic use of lysergic acid diethylamide (LSD) has resurfaced in the last decade, prompting further scientific investigation into its effectiveness in many animal models. Zebrafish (Danio rerio) are a popular model organism in medical sciences and are used to examine the repeated administration of pharmacological compounds. Previous zebrafish research found acute LSD altered behaviour...
Pilot and Feasibility Studies
February 12, 2024
Alesha Wells, A P Suresh Muthukumaraswamy, Eva Morunga et al.
10 citations
An advanced cancer diagnosis can be associated with a significant profile of distress. Psychedelic compounds have shown clinically significant effects in the treatment of psychological distress in patients with advanced-stage cancer. Given the challenges of delivering timely and effective intervention in the advanced cancer context, it is possible that an alternative, more pragmatic, approach...
Journal of Psychoactive Drugs
February 10, 2024
Alyssa F. Harlow, Peter S. Hendricks, Adam M. Leventhal et al.
6 citations
Despite common depictions in the media, there is little scientific evidence on microdosing psychedelic drugs. We assessed awareness, prevalence, and dosing practices of microdosing psychedelic drugs among young adults 18-22 years old from Southern California (2018-2019). We examined whether sociodemographic factors, personality traits, mental health, or other substance use behaviors were...
BMC Neuroscience
February 5, 2024
Robin J Murphy, Kate Godfrey, Alexander D Shaw et al.
16 citations
Microdosing psychedelics is a phenomenon with claimed cognitive benefits that are relatively untested clinically. Pre-clinically, psychedelics have demonstrated enhancing effects on neuroplasticity, which cannot be measured directly in humans, but may be indexed by non-invasive electroencephalography (EEG) paradigms. This study used a visual long-term potentiation (LTP) EEG paradigm to test the...
Frontiers in Pharmacology
February 2, 2024
Joachim Neumann, Stefan Dhein, Uwe Kirchhefer et al.
12 citations
Hallucinogenic drugs are used because they have effects on the central nervous system. Their hallucinogenic effects probably occur via stimulation of serotonin receptors, namely, 5-HT 2A -serotonin receptors in the brain. However, a close study reveals that they also act on the heart, possibly increasing the force of contraction and beating rate and may lead to arrhythmias. Here, we will review...
Journal of Psychedelic Studies
February 1, 2024
Jeremy Weleff, Akhil Anand, Elizabeth N. Dewey et al.
8 citations
Abstract Background Lysergic acid diethylamide (LSD) use has risen in the United States in recent years amid increased interest in therapeutic applications of psychedelics. Despite this, contemporary epidemiological investigations of LSD users are few. To expand the literature on this topic, we sought to characterize past-year LSD users in the United States and investigate recent demographic...
Drug Testing and Analysis
February 1, 2024
Simon D. Brandt, Pierce V. Kavanagh, Folker Westphal et al.
5 citations
Preclinical investigations have shown that N-ethyl-N-isopropyllysergamide (EIPLA) exhibits lysergic acid diethylamide (LSD)-like properties, which suggests that it might show psychoactive effects in humans. EIPLA is also an isomer of N6 -ethylnorlysergic acid N,N-diethylamide (ETH-LAD), a lysergamide known to produce psychedelic effects in humans that emerged as a research chemical. EIPLA was...
Current Medical Research and Opinion
February 1, 2024
Dakota Sicignano, Adrían V. Hernández, Benjamin Schiff et al.
19 citations
Critique the available systematic review and de novo assessment of the role of psychedelics in the treatment of alcohol use disorder. A systematic literature search of PubMed was completed from 1960 to 9/9/2023. We pooled randomized controlled trials comparing psychedelics to control therapy for the treatment of alcohol use disorder. At the first recorded follow-up, LSD [n = 3, Odds Ratio (OR)...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
February 1, 2024
Friederike Holze, Nirmal Singh, Matthias E. Liechti et al.
50 citations
Psychedelic compounds, including psilocybin, LSD (lysergic acid diethylamide), DMT (N,N -dimethyltryptamine), and 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), all of which are serotonin 2A receptor agonists, are being investigated as potential treatments. This review aims to summarize the current clinical research on these 4 compounds and mescaline to guide future research. Their mechanism(s)...
Revista Intertox de Toxicologia Risco Ambiental e Sociedade
January 31, 2024
Gabriela Gadelha Rattacaso, Raíssa Almeida de Moraes, Tatiana Paschoalette Rodrigues Bachur
1 citation
Drogas psicodélicas, a exemplo da dietilamida do ácido lisérgico (LSD), são substâncias psicoativas usadas em diversos contextos socioculturais e que, nas últimas décadas, têm ganhado atenção especial quanto a possibilidade de seu uso no tratamento psiquiátrico de alguns transtornos mentais. Neste contexto, o objetivo do presente estudo foi revisar a literatura científica a fim de elucidar os...